The DOI matches its Crossref record.
Intravenous Nimodipine West European Stroke Trial (INWEST) of Nimodipine in the Treatment of Acute Ischaemic Stroke
Abstract
A randomised, double-blind, placebo-controlled trial of intravenous nimodipine was conducted in 295 patients with acute ischaemic stroke. Nimodipine was given as an intravenous infusion of 1 or 2 mg/h for 5 days followed by an oral dose of 120 mg daily for a total treatment period of 21 days. Patients with a clinical diagnosis of ischaemic stroke in the carotid artery territory within 24 h entered the study at 34 centres, involving 11 European countries: 100 were randomly assigned to placebo, 101 to nimodipine with an initial intravenous dose of 1 mg/h and 94 patients to an initial dose of 2 mg/h. The trial, initially aiming at a patient inclusion of 600, was terminated because of concerns arising from safety monitoring. Primary efficacy variables were neurological outcome according to the Orgogozo scale and functional outcome according to the Barthel scale at day 21. There were apparent differences between the groups in neurological and functional outcome with a better outcome in the placebo group. The differences between the placebo group and the 2-mg/h group were statistically significant (p = 0.0005 for the Orgogozo scale and p = 0.0033 for the Barthel scale). The differences were even more pronounced at the final follow-up at 24 weeks (p = 0.0001 and p = 0.0002, respectively). There were no statistically significant differences in mortality between the groups. There were statistically significant differences between the groups regarding the effect of the first few days of intravenous treatment on systolic and diastolic blood pressure with the most pronounced reduction in the 2-mg/h nimodipine treatment group at day 2 (p = 0.0001). An explorative analysis indicated a correlation between diastolic blood pressure reduction in the nimodipine-treated groups and unfavourable neurological outcome (p = 0.0005). A potential neuroprotective effect of nimodipine by preventing calcium overload in ischaemic neurons may thus have been outweighed by detrimental haemodynamic effects in the ischaemic area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2018) · Stroke · doi:10.1161/str.0000000000000158 · Cited by 5,446
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.181486 · Cited by 2,475
Adams, H. P., Adams, R. J., Brott, T., del Zoppo, G. J., Furlan, A., Goldstein, L. B., Grubb, R. L., Higashida, R., Kidwell, C., Kwiatkowski, T. G., et al. (2003) · Stroke · doi:10.1161/01.str.0000064841.47697.22 · Cited by 1,245
Adams, H. P., del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass, L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C., Kidwell, C., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181486 · Cited by 904
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
The ACCESS Study: Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors
Schrader, J., Lüders, S., Kulschewski, A., Berger, J., Zidek, W., Treib, J., Einhäupl, K., Diener, H. C., & Dominiak, P. (2003) · Stroke · doi:10.1161/01.str.0000075777.18006.89 · Cited by 652
Thrombolytic Therapy with Streptokinase in Acute Ischemic Stroke
(1996) · New England Journal of Medicine · doi:10.1056/nejm199607183350301 · Cited by 570
Sandset, E. C., Bath, P. M., Boysen, G., Jatuzis, D., Kõrv, J., Lüders, S., Murray, G. D., Richter, P. S., Roine, R. O., Terént, A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60104-9 · Cited by 541
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Muir, K. W., & Lees, K. R. (1995) · Stroke · doi:10.1161/01.str.26.3.503 · Cited by 502
Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
De Keyser, J., Sulter, G., & Luiten, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01463-0 · Cited by 374
Self-citationTreatment in a Combined Acute and Rehabilitation Stroke Unit: Which Aspects Are Most Important?
Indredavik, B., Bakke, F., Slørdahl, S. A., Rokseth, R., & Håheim, L. L. (1999) · Stroke · doi:10.1161/01.str.30.5.917 · Cited by 368
Self-citationAhmed, N., Wahlgren, N., Brainin, M., Castillo, J., Ford, G. A., Kaste, M., Lees, K. R., & Toni, D. (2009) · Stroke · doi:10.1161/strokeaha.109.548602 · Cited by 359
Self-citationEffect of Intravenous Nimodipine on Blood Pressure and Outcome After Acute Stroke
Ahmed, N., Näsman, P., & Wahlgren, N. G. (2000) · Stroke · doi:10.1161/01.str.31.6.1250 · Cited by 324
Self-citationMarik, P. E., & Varon, J. (2007) · Chest · doi:10.1378/chest.06-2490 · Cited by 285
Stroke Unit Treatment: Long-term Effects
Indredavik, B., Slørdahl, S. A., Bakke, F., Rokseth, R., & Håheim, L. L. (1997) · Stroke · doi:10.1161/01.str.28.10.1861 · Cited by 284
Self-citationSacco, R. L., DeRosa, J. T., Haley, Jr., Levin, B., Ordronneau, P., Phillips, S. J., Rundek, T., Snipes, R. G., Thompson, J. L. P., & for the GAIN Americas Investigators (2001) · JAMA · doi:10.1001/jama.285.13.1719 · Cited by 283
Stroke Unit Treatment: 10-Year Follow-Up
Indredavik, B., Bakke, F., Slørdahl, S. A., Rokseth, R., & Håheim, L. L. (1999) · Stroke · doi:10.1161/01.str.30.8.1524 · Cited by 263
Self-citationNXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials
Diener, H.-C., Lees, K. R., Lyden, P., Grotta, J., Davalos, A., Davis, S. M., Shuaib, A., Ashwood, T., Wasiewski, W., Alderfer, V., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.503334 · Cited by 255
The Optimising Analysis of Stroke Trials (OAST) Collaboration (2007) · Stroke · doi:10.1161/strokeaha.106.474080 · Cited by 192
An Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Weaver, C. S., Leonardi-Bee, J., Bath-Hextall, F. J., & Bath, P. M. W. (2004) · Stroke · doi:10.1161/01.str.0000125010.70652.93 · Cited by 67
Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors?
The Optimising the Analysis of Stroke Trials (OAST) Collaboration (2009) · Stroke · doi:10.1161/strokeaha.108.519207 · Cited by 64
Metadata
- Authors
- Wahlgren, N. G., MacMahon, D. G., De Keyser, J., Indredavik, B., & Ryman, T.
- Venue
- Cerebrovascular Diseases
- Publisher
- S. Karger AG
- Published
- 1994
- Volume
- 4
- Issue
- 3
- Pages
- 204-210
- ISSN
- 1015-9770 (ISSN-L)
- 1421-9786
- OpenAlex
- W2043610467
- Cited by
- 279
- References
- 0
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.